Business
Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the results of a product expansion meeting with InnoVision Therapeutics, our partner for the Vitalzul™ FDA/CVM submission.\n The market for Pet medicines, supplements, food and treats is ever growing. According to the American Pet Products Association (APPA), the U.S. Pet Industry expenditures surpassed $60B in 2015(1). Breakdown:             Food                                                    $23 Billion             Supplies/OTC Medicine                          $14 Billion             Vet Care                                              $15 Billion             Live animal purchases                             $2 Billion             Pet Services: grooming & boarding           $5 Billion With this in mind, the management of both companies met to discuss expanding Petlife’s existing product line with additional natural based products that InnoVision has already formulated and produced for the human market. These products have a veterinarian application and address some of the most common medical conditions seen in companion pets. The demand for natural based products continues to rise as pets are living longer and serious life threatening diseases are becoming more preva...